BioSpace News Archive

Thermo Fisher and NX Prenatal to develop clinical mass spectrometry-based workflows for monitoring maternal and fetal health during pregnancy and evaluating risk of complications

Aurora Cannabis Inc. (“Aurora”) (NYSE: ACB) (TSX: ACB) (Frankfurt: 21P; WKN: A1C4WM) and Hempco Food and Fiber Inc. (“Hempco”) (TSX-V: HEMP) today announced that the companies have entered into a binding letter agreement (the “Letter Agreement”) in regard to the basic terms and conditions upon which Aurora will acquire all of the issued and outstanding common shares of Hempco

Tecnoplanta Expands its Portfolio with MyoPro®

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, highlighted new data from multiple studies of rezafungin, the company’s lead investigational compound, this week during the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Amsterdam, Netherlands.

On March 11, 2019, ACEA Biosciences – A Part of Agilent unveiled the new xCELLigence® RTCA ePacerTM during their workshop held at the Society of Toxicology (SOT) Annual Meeting in Baltimore.

Biotech and cleantech finance veteran to manage company’s financing and financial operations

Horizon Pharma plc (Nasdaq: HZNP) in partnership with Gift of Adoption today announced the creation of the #RAREis Adoption Fund to help facilitate global adoptions of children with rare diseases. Children awaiting adoption with rare diseases often go untreated or receive minimal treatment, and many face life in a long-term care facility or nursing home, according to Gift of Adoption.

Family Counseling Associates announced the opening of its new facility in Danvers, Massachusetts, and appointed five new clinicians to its team.

The doctor was not in recently. In fact, hundreds of doctors, scientists and researchers from around the world were away from their offices, gathered in Mallorca, Spain for the 8th International IVIRMA Congress on Reproductive Medicine, April 4-6.

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host its annual Science Day for analysts and investors on Tuesday, May 7, 2019 at 8:00 a.m. ET in Cambridge, MA.